Would you ever choose FOLFOXIRI over FOLFOX for high risk Stage III colon adenocarcinoma with multiple adverse prognostic features?

We are frequently confronted in the clinic with a patient with "high risk" stage 3 colon cancer, most commonly with multiple positive lymph nodes. While our gut reaction might be to treat "aggressively", there are no data supporting FOLFOXIRI in the adjuvant setting. In fact, several adjuvant studie...

I fully agree with Dr Grothey’s expertise on use of CAPOX (preferred) or FOLFOX until further data is available. Beyond the planned trials Dr Grothey referred to, a phase III trial in France and Canada should also help elucidate this clinically important question. The IROCAS study (NCT02967289) is a...